Dose–response relationship of sleep apnea therapy and healthcare use in patients with comorbidities
PAP therapy use is associated with dose-dependent reductions in HCRU among patients with OSA and major comorbidities. These findings may support data-driven reimbursement policies and highlight the value of treating OSA in complex patient populations.
Authors
- Suyog More (ORCID: https://orcid.org/0009-0000-4237-0411)
- Naomi Alpert (ORCID: https://orcid.org/0000-0002-3625-9693)
- Adam Benjafield (ORCID: https://orcid.org/0000-0003-4716-2827)
- Atul Malhotra (ORCID: https://orcid.org/0000-0002-9509-1827)
- Caleb Woodford (ORCID: https://orcid.org/0000-0003-1107-8607)
- Jean‐Louis Pépin (ORCID: https://orcid.org/0000-0003-3832-2358)
- Kate Cole (ORCID: https://orcid.org/0000-0001-9008-9229)
- Peter A. Cistulli (ORCID: https://orcid.org/0000-0002-7920-4924)
- K.L. Sterling (ORCID: https://orcid.org/0000-0002-6482-3562)
Institutions
- The University of Sydney (AU)
- University of California San Diego (US)
- La Jolla Alcohol Research (US)
- ResMed (United States) (US)
- Greenfield Research (Canada) (CA)
- Nova Scotia Cancer Centre (CA)
- ScienceMedia (United States) (US)
- ResMed (Australia) (AU)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- SLEEP
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1093/sleep/zsaf333
- Citations
- 1
- Primary Topic
- Obstructive Sleep Apnea Research
- Type
- article
- Field-Weighted Citation Impact
- 1.16